Craft

Kinnate Biopharma

Stock Price

$2.7

2024-04-03

Market Capitalization

$125 M

2024-04-03

Kinnate Biopharma Summary

Company Summary

Overview
Kinnate Biopharma is a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. It utilizes its expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which the company refers to as the Kinnate Discovery Engine, to develop targeted therapies.
Type
Public
Status
Active
Founded
2018
HQ
San Diego, CA, US | view all locations
Website
https://www.kinnate.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Nima Farzan
  • Mark Meltz

    Mark Meltz, COO & General Counsel

  • Neha Krishnamohan

    Neha Krishnamohan, CFO & EVP, Corporate Development

    • Richard Williams

      Richard Williams, Chief Medical Officer

    Operating MetricsView all

    New Chemical Entities

    3.3K

    Q3, 2020

    Drug Metabolism and Pharmacokinetics Studies

    4K

    Q3, 2020

    Unique In Vitro Assays

    170

    Q3, 2020

    LocationsView all

    1 location detected

    • San Diego, CA HQ

      United States

      3611 Valley Centre Dr #175

    Kinnate Biopharma Financials

    Summary Financials

    Net income (FY, 2023)
    ($112.6M)
    Cash (FY, 2023)
    $57.0M
    EBIT (FY, 2023)
    ($121.2M)
    Enterprise value
    $71.2M

    Footer menu